We are live on
!
Find out more
AG
Artal Group Portfolio holdings
AUM
$1.01B
1-Year Est. Return
29.84%
This Fund
S&P 500
This Quarter
Est. Return
+17.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.66B
AUM Growth
+$1B
(+21%)
Cap. Flow
+$784M
Cap. Flow
% of AUM
13.85%
Top 10 Holdings %
Top 10 Hldgs %
43.17%
Holding
164
New
34
Increased
29
Reduced
25
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$47.7M |
| 2 |
argenx
ARGX
|
+$47.4M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$44.5M |
| 4 |
IMA
ImageneBio Inc
IMA
|
+$44.2M |
| 5 |
ACHL
Achilles Therapeutics
ACHL
|
+$37.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GDS Holdings
GDS
|
+$89.7M |
| 2 |
Zillow
Z
|
+$66.8M |
| 3 |
ONC
BeOne Medicines Ltd
ONC
|
+$49.7M |
| 4 |
Alibaba
BABA
|
+$46.5M |
| 5 |
uniQure
QURE
|
+$25.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.71% |
| 2 | Consumer Discretionary | 8.71% |
| 3 | Technology | 1.72% |
| 4 | Communication Services | 0.79% |
| 5 | Real Estate | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
| – | – |
-200,000
| Closed | -$26M |
|
|
152
CALL
Alibaba
BABA
$276B
| – | – |
-200,000
| Closed | -$46.5M |
|
|
153
Alibaba
BABA
$276B
| – | – |
-200,000
| Closed | -$46.5M |
|
154
Bruker
BRKR
$9.4B
| – | – |
-175,275
| Closed | -$9.49M |
|
155
Celldex Therapeutics
CLDX
$2.94B
| – | – |
-400,000
| Closed | -$7.01M |
|
156
Cytokinetics
CYTK
$10.6B
| – | – |
-500,000
| Closed | -$10.4M |
|
157
Danaher
DHR
$138B
| – | – |
-56,400
| Closed | -$11.1M |
|
|
KYNB
158
Kyntra Bio
KYNB
$27.4M
| – | – |
-16,000
| Closed | -$14.8M |
|
|
FOLD
159
CALL
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-1,000,000
| Closed | -$23.1M |
|
160
Moderna
MRNA
$21.6B
| – | – |
-50,000
| Closed | -$5.22M |
|
161
ProQR Therapeutics
PRQR
$244M
| – | – |
-1,196,218
| Closed | -$5.02M |
|
|
162
uniQure
QURE
$2.75B
| – | – |
-700,000
| Closed | -$25.3M |
|
163
Bio-Techne
TECH
$11.2B
| – | – |
-240,000
| Closed | -$19.1M |
|
|
ACGN
164
DELISTED
Aceragen Inc
ACGN
| – | – |
-29,441
| Closed | -$1.83M |
|
Similar funds
BCM
GA
EPAM
WA
CT
AH
PIM
MAM
Artal Group's Q1 2021 Portfolio in Review
As of Q1 2021, Artal Group held 164 positions worth $5.66B, up 21% from $4.66B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Artal Group deployed $784M of net new capital in Q1 2021, opening 34 new positions and adding to 29 existing holdings. Its largest new stake was Intel: 800,000 shares worth $51.2M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 77% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was GDS Holdings, an estimated $89.7M trimmed.
- Artal Group's largest Q1 2021 buy was Intel: 800,000 shares worth $51.2M.
- Artal Group added most to argenx in Q1 2021, an estimated $47.4M increase.
- Artal Group's biggest Q1 2021 reduction was GDS Holdings, cutting an estimated $89.7M.
- Artal Group fully exited Alibaba in Q1 2021, selling an estimated $46.5M.
- Artal Group's ten largest holdings make up 43% of its $5.66B portfolio in Q1 2021.
- Artal Group opened 34 new positions and closed 18 in Q1 2021.
- Artal Group's portfolio value rose 21% quarter-over-quarter to $5.66B.
Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.